Accuray (ARAY) Cash from Investing Activities (2010 - 2026)
Accuray's (ARAY) quarterly Cash from Investing Activities came in at -$1.5 million in Q1 2026, up 70.59% year-on-year from -$882809.8 in Q1 2025, and up 73.09% quarter-over-quarter from -$5.6 million in Q4 2025.
Accuray (ARAY) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Accuray's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 70.59% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$16.0 million, a 46.59% decrease from a year earlier, with the FY2025 full-year figure at -$8.5 million, down 136.68% from the prior year.
- Cash from Investing Activities grew to -$1.5 million in Q1 2026 per ARAY's latest filing, from -$5.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$1.1 million in Q3 2023 and bottomed at -$5.6 million in Q4 2025.
- The 5-year median for Cash from Investing Activities is -$1.6 million (2024), against an average of -$2.7 million.
- Across the five-year window, Cash from Investing Activities slumped 256.43% in 2025 and jumped 70.59% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$1.5 million in 2022, then climbed by 18.58% to -$1.2 million in 2023, then slipped by 25.7% to -$1.6 million in 2024, then slumped by 256.43% to -$5.6 million in 2025, then surged by 73.09% to -$1.5 million in 2026.
- Per Business Quant, the three latest ARAY Cash from Investing Activities figures stand at -$1.5 million (Q1 2026), -$5.6 million (Q4 2025), and -$3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.81 Bn | 99.59 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.39 Bn | 66.94 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.28 Bn | 44.60 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.30 Bn | 26.01 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Accuray | 28,254.30 | -38.51 Mn | 25.29 Mn | -1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.51 Mn |
| Mar 31, 2026 | -1.51 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Dec 31, 2025 | -5.60 Mn |
| Sep 30, 2025 | -3.82 Mn |
| Sep 30, 2025 | -3.82 Mn |
| Mar 31, 2025 | -5.12 Mn |
| Mar 31, 2025 | -5.12 Mn |
| Dec 31, 2024 | -1.57 Mn |
| Dec 31, 2024 | -1.57 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Sep 30, 2024 | -1.12 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Dec 31, 2023 | -1.25 Mn |
| Dec 31, 2023 | -1.25 Mn |
| Sep 30, 2023 | -1.09 Mn |
| Sep 30, 2023 | -1.09 Mn |
| Mar 31, 2023 | -4.71 Mn |
| Mar 31, 2023 | -4.71 Mn |